**Appendix 1: An example of a network geometry with three treatments**

****

This figure illustrates an example where we want to compare three treatments (A, B and C) using the mean difference (MD). In this example, there was one trial that compared A vs. B and found a MD of 4.0 (95% confidence interval (CI) 3.0 to 5.0) and one trial that compared A vs. C with a MD of 2.3 (95% CI 1.4 to 3.2). From this hypothetical comparison, we can see that B and C are likely better than A if a reduction is desirable. If the trial samples are clinically homogenous, then we can estimate that B is better than C by 1.7 (95% CI 0.4 to 3.0) through an indirect comparison. If a new trial was then conducted that compared B and C directly, network meta-analysis could combine the indirect estimate of B to C (1.7) and the resulting direct estimate from the new trial.

**Appendix 2: Network Geometry for Bacteremia with Separate Control Groups (Placebo, No Antibiotic and Non-absorbable Antibiotic Separate)**

****

Geometry illustrates direct and indirect comparisons in the network. Link thickness reflects the number of studies.

**Appendix 3: Network Geometry for Bacteremia with Placebo or No Antibiotic Control Groups Combined**



Geometry illustrates direct and indirect comparisons in the network. Link thickness reflects the number of studies.

**Appendix 4: Network Geometry for Bacteremia with Placebo, No Antibiotic and Non-Absorbable Antibiotic (All Control Groups) Combined**

****

Geometry illustrates direct and indirect comparisons in the network. Link thickness reflects the number of studies.

**Appendix 5: Characteristics of Included Studies in Systematic Review (N=113)**

|  |  |
| --- | --- |
| **Characteristic and Strata** | **No. Studies (%)** |
| **Study Population Characteristics**  |  |
| Treatment |  |
|  Cancer patients receiving chemotherapy only | 73 (65%) |
|  Hematopoietic stem cell transplantation  | 19 (17%) |
|  Both chemotherapy and transplantation | 21 (18%) |
| Age participants |  |
|  Adult  | 75 (66%) |
|  Pediatric  | 13 (12%) |
|  Both | 18 (16%) |
|  Not stated | 7 (6%) |
|  |  |
| **Risk of Bias** |  |
| Adequate sequence generation | 24 (21%) |
| Adequate allocation concealment | 21 (19%) |
| Participants and personnel blinded | 27 (24%) |
| Outcome assessors blinded | 11 (10%) |
| Lack of attrition bias | 70 (62%) |
| Free of selective reporting | 33 (29%) |

**Appendix 6: Pairwise comparisons in the network meta-analysis for outcome of bacteremia with all control groups combined\***

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Glyco** | **Fluoro + NAPBL** | **Fluoro** | **None** | **Fluoro + glyco** | **Cephalo** | **NAPBL** | **Fluoro + macro** | **Fluoro + rifamycin** | **TMP-SMX** | **Fluoro + TMP-SMX** | **Quino** | **Fluoro + placebo** | **Amino + APBL + glyco** | **TMP** | **Cephalo + glyco** | **TMP-SMX < daily** | **Amino + APBL + NAPBL** |
| **Glyco** | NA | 0.6(0.2, 1.6) | 0.9(0.4, 1.8) | 1.5(0.8, 3.1) | 0.2(0.1, 0.8) | 0.4(0.2, 1.1) | 0.7(0.2, 2.0) | 0.7(0.2, 2.0) | 0.2(0.1, 0.7) | 0.8(0.4, 1.8) | 0.3(0.0, 4.7) | 1.3(0.6, 3.3) | 0.9(0.3, 3.3) | 0.1(0.0, 0.9) | 0.1(0.0, 1.3) | 0.3(0.0, 1.8) | 0.6(0.2, 1.8) | 0.1(0.0, 1.2) |
| **Fluoro + NAPBL** | 1.7(0.6, 4.4) | NA | 1.4(0.7, 2.9) | 2.5(1.3, 5.0) | 0.4(0.1, 1.4) | 0.7(0.3, 1.7) | 1.1(0.4, 3.2) | 1.1(0.4, 3.2) | 0.4(0.1, 1.2) | 1.4(0.8, 2.9) | 0.5(0.0, 7.7) | 2.2(1.0, 5.3) | 1.5(0.7, 3.5) | 0.2(0.0, 1.5) | 0.2(0.0, 2.2) | 0.5(0.1, 2.9) | 0.9(0.3, 3.0) | 0.1(0.0, 2.0) |
| **Fluoro** | 1.2(0.6, 2.4) | 0.7(0.4, 1.4) | NA | 1.7(1.4, 2.3) | 0.3(0.1, 0.8) | 0.5(0.3, 0.9) | 0.8(0.3, 1.8) | 0.8(0.3, 1.8) | 0.3(0.1, 0.6) | 1.0(0.7, 1.3) | 0.4(0.0, 5.0) | 1.6(0.9, 2.7) | 1.1(0.4, 3.1) | 0.1(0.0, 0.9) | 0.2(0.0, 1.4) | 0.4(0.0, 1.8) | 0.7(0.3, 1.7) | 0.1(0.0, 1.3) |
| **None** | 0.7(0.3, 1.3) | 0.4(0.2, 0.8) | 0.6(0.4, 0.7) | NA | 0.2(0.0, 0.5) | 0.3(0.2, 0.5) | 0.4(0.2, 1.0) | 0.5(0.2, 1.0) | 0.2(0.1, 0.4) | 0.6(0.4, 0.8) | 0.2(0.0, 2.9) | 0.9(0.5, 1.5) | 0.6(0.2, 1.8) | 0.1(0.0, 0.5) | 0.1(0.0, 0.8) | 0.2(0.0, 1.0) | 0.4(0.1, 1.0) | 0.0(0.0, 0.7) |
| **Fluoro + glyco** | 4.6(1.2, 20.0) | 2.8(0.7, 12.0) | 3.9(1.2, 14.0) | 6.9(2.2, 25.0) | NA | 2.0(0.5, 8.0) | 3.0(0.7, 14.0) | 3.1(0.7, 14.0) | 1.1(0.3, 5.1) | 3.8(1.1, 14) | 1.4(0.0, 27.0) | 6.1(1.7, 25.0) | 4.2(0.9, 22.0) | 0.5(0.0, 5.4) | 0.7(0.0, 7.8) | 1.5(0.1, 11.0) | 2.6(0.6, 13.0) | 0.3(0.0, 6.7) |
| **Cephalo** | 2.3(1.0, 5.9) | 1.4(0.6, 3.5) | 2.0(1.1, 3.9) | 3.5(2.0, 6.6) | 0.5(0.1, 1.9) | NA | 1.5(0.5, 4.4) | 1.6(0.6, 4.4) | 0.6(0.2, 1.6) | 1.9(1.0, 3.9) | 0.7(0.0, 11.0) | 3.1(1.4, 7.1) | 2.1(0.6, 7.4) | 0.3(0.0, 2.0) | 0.3(0.0, 3.0) | 0.8(0.1, 4.1) | 1.3(0.4, 4.1) | 0.1(0.0, 2.8) |
| **NAPBL** | 1.5(0.5, 4.7) | 0.9(0.3, 2.8) | 1.3(0.6, 3.2) | 2.3(1.0, 5.6) | 0.3(0.1, 1.4) | 0.7(0.2, 1.9) | NA | 1.0(0.3, 3.4) | 0.4(0.1, 1.2) | 1.3(0.6, 3.0) | 0.5(0.0, 7.6) | 2.0(0.8, 5.7) | 1.4(0.4, 5.5) | 0.2(0.0, 1.5) | 0.2(0.0, 2.1) | 0.5(0.1, 3.0) | 0.9(0.3 3.0) | 0.1(0.0, 2.0) |
| **Fluoro + macro** | 1.5(0.5, 4.5) | 0.9(0.3, 2.6) | 1.3(0.6, 3.0) | 2.2(1.0, 5.4) | 0.3(0.1, 1.4) | 0.6(0.2, 1.8) | 1.0(0.3, 3.3) | NA | 0.4(0.1, 1.2) | 1.2(0.5, 3.0) | 0.5(0.0, 7.4) | 2.0(0.8, 5.4) | 1.4(0.4, 5.3) | 0.2(0.0, 1.4) | 0.2(0.0, 2.1) | 0.5(0.1, 2.9) | 0.8(0.2, 3.0) | 0.1(0.0, 1.9) |
| **Fluoro + rifamycin** | 4.2(1.4, 14.0) | 2.5(0.9, 7.9) | 3.6(1.6, 9.0) | 6.2(2.6, 16.0) | 0.9(0.2, 4.) | 1.8(0.6, 5.5) | 2.7(0.8, 9.6) | 2.8(0.9, 9.6) | NA | 3.4(1.4, 9.1) | 1.3(0.0, 21.0) | 5.6(2.1, 16.0) | 3.8(1.0, 16.0) | 0.5(0.0, 4.2) | 0.6(0.0, 6.0) | 1.3(0.1, 8.5) | 2.4(0.7, 8.8) | 0.3(0.0, 5.4) |
| **TMP-SMX** | 1.2(0.6, 2.6) | 0.7(0.4, 1.5) | 1,0(0.8, 1.4) | 1.8(1.3, 2.6) | 0.3(0.1, 0.9) | 0.5(0.3, 1.0) | 0.8(0.3, 1.8) | 0.8(0.3, 1.9) | 0.3(0.1, 0.7) | NA | 0.4(0.0, 5.1) | 1.6(0.9, 2.9) | 1.1(0.4, 3.3) | 0.1(0.0, 1.0) | 0.2(0.0, 1.4) | 0.4(0.0, 1.9) | 0.7(0.3, 1.7) | 0.1(0.0, 1.4) |
| **Fluoro + TMP-SMX** | 3.3(0.2, >99) | 2.0(0.1, 66.0) | 2.8(0.2, 89.0) | 4.9(0.4, >99) | 0.7 (0.0, 26.0) | 1.4(0.1, 46.0) | 2.1(0.1, 72.0) | 2.2(0.1, 75.0) | 0.8(0.0, 27.0) | 2.7(0.2, 84.0) | NA | 4.4(0.3, >99) | 3.0(0.2, >99) | 0.3(0.0, 20.0) | 0.5(0.0, 25.0) | 1.0(0.0, 47.0) | 1.8(0.1, 64.0) | 0.2(0.0, 18.0) |
| **Quino** | 0.8(0.3, 1.8) | 0.5(0.2, 1.1) | 0.6(0.4, 1.1) | 1.1(0.7, 2.0) | 0.2(0.0, 0.6) | 0.3(0.1, 0.7) | 0.5(0.2, 1.3) | 0.5(0.2, 1.3) | 0.2(0.1, 0.5) | 0.6(0.3, 1.1) | 0.2(0.0, 3.4) | NA | 0.7(0.2, 2.2) | 0.1(0.0, 0.6) | 0.1(0.0, 0.9) | 0.2(0.0, 1.3) | 0.4(0.1, 1.2) | 0.0(0.0, 0.9) |
| **Fluoro + placebo** | 1.1 (0.3, 4.0) | 0.7(0.3, 1.5) | 0.9(0.3, 2.8) | 1.7(0.6, 4.9) | 0.2(0.0, 1.2) | 0.5(0.1, 1.6) | 0.7(0.2, 2.8) | 0.7(0.2, 2.9) | 0.3(0.1, 1.0) | 0.9(0.3, 2.8) | 0.3(0.0, 5.8) | 1.5(0.5, 4.9) | NA | 0.1(0.0, 1.2) | 0.2(0.0, 1.7) | 0.4(0.0, 2.4) | 0.6(0.2, 2.6) | 0.1(0.0, 1.5) |
| **Amino + APBL + glyco** | 9.2(1.1, >99) | 5.5(0.7, >99) | 7.7(1.1, >99) | 14.0(1.9, >99) | 2.0(0.2, 72.0) | 3.9(0.5, >99) | 6.0 (0.7, >99) | 6.1(0.7, >99) | 2.2(0.2, 74.0) | 7.5(1.0, >99) | 3.0 (0.1, >99) | 12.0(1.6, >99) | 8.4(0.9, >99) | NA | 1.3(0.0, 67.0) | 3.0(0.2, >99) | 5.2(0.55, >99) | 0.6(0.1, 4.3) |
| **TMP** | 7.1(0.8, >99) | 4.2(0.5, >99) | 6.0(0.7, >99) | 11.0(1.3, >99) | 1.5(0.1, 50.0) | 3.0(0.3, 85.0) | 4.6(0.5, >99) | 4.7(0.5, >99) | 1.7(0.2, 50.0) | 5.8(0.7, >99) | 2.2(0.0, >99) | 9.4(1.1, >99) | 6.5(0.6, >99) | 0.8(0.0, 35.0) | NA | 2.3(0.1, 84.0) | 4.0(0.4, >99) | 0.4(0.0, 34.0) |
| **Cephalo + glyco** | 3.1(0.6, 27.0) | 1.9(0.3, 16.0) | 2.6(0.6, 21.0) | 4.6(1.0, 37.0) | 0.7(0.1, 7.2) | 1.3(0.3, 11.0) | 2.0(0.3, 19.0) | 2.1(0.4, 19.0) | 0.7(0.1, 7.0) | 2.6(0.5, 21.0) | 1.0(0.0, 27.0) | 4.2(0.8, 35.0) | 2.8(0.4, 28.0) | 0.3(0.0, 5.9) | 0.4(0.01, 8.6) | NA | 1.8(0.3, 17.0) | 0.2(0.0, 6.4) |
| **TMP-SMX\_Not\_Daily** | 1.8(0.5, 5.9) | 1.1(0.3, 3.5) | 1.5(0.6, 4.1) | 2.7( 1.0, 7.2) | 0.4(0.1, 1.8) | 0.8(0.2, 2.4) | 1.2(0.3, 4.1) | 1.2(0.3, 4.3) | 0.4(0.1, 1.5) | 1.5(0.6, 3.7) | 0.5(0.0, 8.9) | 2.4(0.8, 7.1) | 1.6(0.4, 6.9) | 0.2(0.0, 1.8) | 0.3(0.0, 2.5) | 0.6(0.1, 3.7) | NA | 0.1(0.0, 2.4) |
| **Amino + APBL + NAPBL** | 17.0(0.8, >99) | 10.0(0.5, >99) | 14.0(0.8, >992) | 25.0(1.4, >99) | 3.7(0.2, >99) | 7.3(0.4, >99) | 11.0(0.5, >99) | 11.0(0.5, >99) | 4.0(0.2, >99) | 14.0(0.7, >99) | 5.2(0.1, >99) | 23.0(1.1, >99) | 15.0(0.7, >99) | 1.7(0.2, 16.0) | 2.3(0.0, >99) | 5.4(0.2, >99) | 9.6(0.4, >99) | NA |

Abbreviations: glyco – parenteral glycopeptide; fluoro – fluoroquinolone; metro – metronidazole; NAPBL – non-antipseudomonal beta lactam; cephalo – cephalosporin; none – placebo, no antibiotic and non-absorbable; macro – macrolide; TMP-SMX – trimethoprim- sulfamethoxazole; quino – quinolone, not fluoroquinolone; amino – aminoglycoside; APBL – antipseudomonal beta lactam; ; granulo- granulocyte infusion

\*Estimate reflects risk ratio with 95% credible region. The row reflects the reference treatment and the column reflects the comparator treatment. Thus, a risk ratio less than 1 suggests that the comparator is better than the reference at reducing the outcome

**Appendix 7: Pairwise comparisons in the network meta-analysis for outcome of infection-related mortality with all control groups combined\***

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Glyco** | **Fluoro + Metro** | **Fluoro + NAPBL** | **Fluoro** | **None** | **Fluoro + glyco** | **Cephalo** | **NAPBL** | **Fluoro + macro** | **Fluoro + rifamycin** | **TMP-SMX** | **Quino** | **Amino + APBL + glyco** | **TMP-SMX + macro** | **TMP** | **Amino + glyco + APBL OR cepahlo + APBL** | **Granulo** |
| **Glyco** | NA | 0.5(0.1, 3.1) | 0.9(0.1, 7.9) | 0.5(0.1, 2.0) | 0.6(0.2, 2.1) | <0.01 (<0.01, 0.4) | 0.2(0.0, 1.5) | 0.2(0.0, 2.3) | 0.2(0.0, 1.2) | 0.1(0.0, 1.6) | 0.3(0.1, 1.0) | 0.5(0.1, 2.3) | <0.01(<0.01, 0.1) | 1.0(0.1, 14.0) | 0.4(0.0, 2.1) | 0.6(0.1, 4.2) | <0.01 (<0.01, 0.1) |
| **Fluoro + Metro** | 2.2(0.3, 15.0) | NA | 1.9(0.3, 17.0) | 1.1(0.3, 4.3) | 1.3(0.3, 5) | <0.01(<0.01, 0.9) | 0.6(0.1, 3.5) | 0.5(0.1, 5.2) | 0.4(0.1, 2.7) | 0.3(0.0, 3.4) | 0.6(0.1, 2.1) | 1.0(0.2, 5.3) | <0.01(<0.01, 0.2) | 2.2(0.2, 32.0) | 0.6(0.2, 4.7) | 1.4(0.2, 9.8) | <0.01(<0.01, 0.2) |
| **Fluoro + NAPBL** | 1.2(0.1, 9.5) | 0.5(0.1, 4.1) | NA | 0.6(0.1, 2.9) | 0.7(0.1, 3.4) | <0.01 (<0.01, 0.5) | 0.3(0.0, 2.3) | 0.3(0.0, 3.2) | 0.2(0.0, 1.7) | 0.1(0.0, 2.1) | 0.3(0.0, 1.5) | 0.5(0.1, 3.5) | <0.01(<0.01, 0.1) | 1.1(0.1, 19.0) | 0.3(0.0, 3.0) | 0.7(0.1, 6.1) | <0.01(<0.01, 0.1) |
| **Fluoro** | 2.0(0.5, 8.1) | 0.9(0.2, 3.3) | 1.7(0.4, 9.9) | NA | 1.1(0.7, 1.7) | <0.01(<0.01, 0.7) | 0.5(0.1, 1.9) | 0.5(0.1, 3.0) | 0.4(0.1, 1.4) | 0.2(0.0, 2.1) | 0.5(0.3, 0.9) | 0.9(0.4, 2.4) | <0.01(<0.01, 0.2) | 1.9(0.2, 21.0) | 0.5(0.2, 2.6) | 1.2(0.3, 5.3) | <0.01(<0.01, 0.2) |
| **None** | 1.7(0.5, 6.8) | 0.8(0.2, 3.2) | 1.5(0.3, 9.2) | 0.9(0.6, 1.4) | NA | <0.01(<0.01, 0.6) | 0.4(0.1, 1.6) | 0.4(0.1, 2.6) | 0.3(0.1, 1.2) | 0.2(0.0, 1.9) | 0.4(0.3, 0.7) | 0.8(0.3, 2.1) | <0.01(<0.01, 0.2) | 1.7(0.2, 18.0) | 0.6(0.2, 2.3) | 1.1(0.3, 4.5) | <0.01(<0.01, 0.2) |
| **Fluoro + glycol** | >99(2.4, >99) | >99(1.2, >99) | >99(2.1, >99) | >99(1.4, >99) | >99(1.6, >99) | NA | >99(0.7, >99) | >99(0.6, >99) | >99(0.5, >99) | >99(0.2, >99) | >99(0.7, >99) | >99(1.2, >99) | 0.0(<0.01, >99) | >99(2.4, >99) | >99(0.7, >99) | >99(1.6, >99) | <0.01(<0.01, >99) |
| **Cephalo** | 4.1(0.7, 32.0) | 1.8(0.3, 15.0) | 3.6 (0.4, 37.0) | 2.1(0.5, 11.0) | 2.3 (0.6, 11.0) | <0.01(<0.01, 1.5) | NA | 1.0(0.1, 11.00) | 0.8(0.1, 5.8) | 0.5(0.0, 7.5) | 1.0(0.3, 5.0) | 1.9 (0.4, 12.0) | <0.01(<0.01, 0.5) | 4.1 (0.3, 66.0) | 1.1(0.1, 10.0) | 2.5 (0.4, 21.0) | <0.01(<0.01, 0.4) |
| **NAPBL** | 4.1(0.4, 41.0) | 1.8(0.2, 19.0) | 3.5 (0.3, 48.0) | 2.1(0.3, 14.0) | 2.3 (0.4, 16.0) | <0.01(<0.01, 1.6) | 1.0(0.1, 10) | NA | 0.9(0.1, 7.8) | 0.5(0.0, 9.2) | 1.0(0.2, 6.5) | 1.9 (0.3, 15.0) | <0.01 (<0.01, 0.4) | 4.1 (0.3, 80.0) | 1.1(0.1, 13.0) | 2.5 (0.2, 26.0) | <0.01(<0.01, 0.4) |
| **Fluoro + macro** | 5.2 0.8, 37.0) | 2.3 (0.4, 17.0) | 4.5 (0.6, 44.0) | 2.6(0.7, 12.0) | 2.9 (0.8, 13.0) | <0.01(<0.01, 2.1) | 1.3(0.2, 9.1) | 1.3(0.1, 13.0) | NA | 0.6(0.0, 8.6) | 1.3(0.3, 5.7) | 2.4 (0.5, 14.0) | <0.01 (<0.01, 0.6) | 5.2 (0.4, 79.0) | 1.4(0.2, 12.0) | 3.1 (0.5, 25.0) | <0.01(<0.01, 0.5) |
| **Fluoro + rifamycin** | 8.6 (0.6, >99) | 3.8 (0.3, >99) | 7.6 (0.5, >99) | 4.2(0.5, >99) | 4.8 (0.5, >99) | <0.01(<0.01, 5.2) | 2.1(0.1, 80.0) | 2.1(0.1, >99) | 1.7(0.1, 62.0) | NA | 2.1(0.2, 68.0) | 3.9 (0.4, >99) | <0.01 (<0..01, 1.4) | 9.0 (0.4, >99) | 2.4(0.2, 97.0) | 5.2 (0.4, >99) | <0.01(<0.01, 1.3) |
| **TMP-SMX** | 4.0(1.1, 17.0) | 1.8 (0.5, 8.0) | 3.5 (0.7, 22.0) | 2.0(1.3, 3.7) | 2.3 (1.5, 3.7) | <0.01 (<0.01, 1.4) | 1.0(0.2, 4.1) | 1.0(0.2, 6.1) | 0.8(0.2, 3.1) | 0.5(0.0, 4.5) | NA | 1.8 (0.8, 4.9) | <0.01 (<0.01, 0.4) | 4.0(0.5, 44.0) | 1.1(0.2, 5.2) | 2.5 (0.6, 12.0) | <0.01(<0.01, 0.4) |
| **Quino** | 2.2 (0.4, 11.0) | 1.0(0.2, 4.9) | 1.9 (0.3, 14.0) | 1.1(0.4, 2.9) | 1.3 (0.5, 3.1) | <0.01(<0.01, 0.8) | 0.5(0.1, 2.7) | 0.5(0.1, 3.9) | 0.4(0.1, 2.0) | 0.3(0.0, 2.8) | 0.5(0.2, 1.3) | NA | <0.01 (<0.01, 0.2) | 2.2 (0.2, 26.0) | 0.6(0.1, 3.4) | 1.3 (0.2, 7.3) | <0.01 (<0.01, 0.2) |
| **Amino + APBL + glyco** | >99(10.0, >99) | >99(4.4, >99) | >99(7.9, >99) | >99(5.2, >99) | >99(5.8, >99) | >99(<0.01, >99) | >99(2.2, >99) | >99(2.3, >99) | >99(1.8, >99) | >99(0.7, >99) | >99(2.5, >99) | >99(4.6, >99) | NA | >99(9.3, >99) | >99((2.5, >99) | >99(5.9, >99) | 0.9(0.2, 3.9) |
| **TMP-SMX + macro** | 1.0(0.1, 12.0) | 0.5 (0.0, 5.6) | 0.9(0.1, 14.0) | 0.5(0.0, 4.4) | 0.6 (0.1, 4.7) | <0.01 (<0.01, 0.4) | 0.2(0.0, 2.9) | 0.2(0.01, 4.0) | 0.2(0.0, 2.3) | 0.1(0.0, 2.6) | 0.3(0.0, 2.1) | 0.5(0.0, 4.7) | <0.01 (<0.01, 0.1) | NA | 0.3(0.0, 3.7) | 0.6(0.0, 7.8) | <0.01(<0.01, 0.1) |
| **TMP** | 3.7 (0.5, 31.0) | 1.6 (0.2, 15.0) | 3.1(0.3, 37.0) | 1.8(0.4, 11.0) | 2.1 (0.4, 11.0) | <0.01 (<0.01, 1.4) | 0.9(0.1, 7.4) | 0.9(0.1, 10.0) | 0.7 (0.1, 5.8) | 0.4(0.0, 6.8) | 0.9(0.2, 4.5) | 1.7 (0.3, 11.0) | <0.01(<0.01, 0.4) | 3.6(0.3, 65.0) | NA  | 2.2 (0.3, 21.0) | <0.01 (<0.01, 0.4) |
| **Amino + glyco + APBL OR cepahlo + APBL** | 1.6 (0.2, 12.0) | 0.7(0.1, 5.6) | 1.4 (0.2, 14.0) | 0.8(0.2, 3.9) | 0.9 (0.2, 4.0) | <0.01 (<0.01, 0.7) | 0.4(0.0, 2.8) | 0.4(0.0, 4.1) | 0.3(0.0, 2.2) | 0.2(0.0 2.8) | 0.4(0.1, 1.8) | 0.8(0.1, 4.4) | <0.01 (<0.01, 0.2) | 1.7 (0.1, 25.0) | 0.5(0.0, 3.8) | NA | <0.01(<0.01, 0.2) |
| **Granulo** | >99 ( 11.0, > 99) | >99(4.7, >99) | >99(8.5, >99) | >99(5.4, >99) | >99(6.1, >99) | >99(0.01, >99) | >99(2.4, >99) | >99(2.4, >99) | >99(1.9, >99) | >99(0.8, >99) | >99(2.6, >99) | >99(4.8, >99) | 1.1(0.3, 4.7) | >99(9.6, >99) | >99(2.6, >99) | >99(6.3, >99) | NA |

Abbreviations: glyco – parenteral glycopeptide; fluoro – fluoroquinolone; metro – metronidazole; NAPBL – non-antipseudomonal beta lactam; cephalo – cephalosporin; none – placebo, no antibiotic and non-absorbable; macro – macrolide; TMP-SMX – trimethoprim- sulfamethoxazole; quino – quinolone, not fluoroquinolone; amino – aminoglycoside; APBL – antipseudomonal beta lactam; ; granulo- granulocyte infusion

\*Estimate reflects risk ratio with 95% credible region. The row reflects the reference treatment and the column reflects the comparator treatment. Thus, a risk ratio less than 1 suggests that the comparator is better than the reference at reducing the outcome